Biosimilar adalimumab is a test of shared decision making in the NHS

Co-written by the National Rheumatoid Arthritis Society, National Ankylosing Spondylitis Society, RNIB, Birdshot Uveitis Society, Psoriasis Association and Crohn’s & Colitis UK

The entry of new biosimilars and the creation of an NHS ‘local market of treatment options’ will see significant numbers of patients switched from the originator product, Humira, to one of four biosimilar alternatives this year.

Adalimumab is one of several biological drugs used in the treatment of autoimmune inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, non-infectious posterior uveitis, Crohn’s and colitis.

While some patients will take this in their stride, for others the change will be met with feelings of apprehension. Read more Biosimilar adalimumab is a test of shared decision making in the NHS

Biosimilars: a great opportunity for pharmacists in England

by Jonathan Campbell, RPS Regional Liaison Pharmacist

Biosimilars have huge benefits for patients and the NHS and offer opportunities for pharmacists too.

The NHS Long Term Plan sets out how “the NHS will move to a new service model in which patients get more options, better support, and properly joined-up care at the right time in the optimal care setting”.

These new models of integrated care will need organisations and their staff to work together across the traditional boundaries of community, general practice and hospital – adopting a system leadership approach to improving population health that puts the patient at its heart. Read more Biosimilars: a great opportunity for pharmacists in England